SHANGHAI, China, May 20, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Net revenue increased by 12.0% year-over-year (“Y-o-Y”) to RMB2,723.2 million (US$375.3 million) in the first quarter of 2025 (1Q2024: RMB2,432.2 million).Net income ...

Investor Presentation - Financial Results Q1 2025 Attachments Q1 2025 Investor Presentation Q1 2025 Investor Presentation ...

Core Insights - Pasithea Therapeutics Corp. has announced new preclinical data indicating that PAS-004, a next-generation macrocyclic MEK inhibitor, demonstrates superior inhibition of ETS2-driven inflammatory responses compared to the FDA-approved MEK inhibitor selumetinib in a human macrophage model of chronic inflammation [1][3] Group 1: Study Findings - The study conducted at the Francis Crick Institute shows that PAS-004 consistently outperforms selumetinib across all tested doses (0.01 μM, 0.1 μM, and 1 μM), indicating more robust and durable MEK inhibition under inflammatory conditions [2][3] - PAS-004 exhibits superior suppression of ETS2 signaling, with greater downregulation of ETS2-regulated genes than selumetinib at all doses tested [3][4] - PAS-004 significantly reduces ETS2-dependent macrophage functions such as cytokine production, phagocytosis, and reactive oxygen species (ROS) generation, which are central to chronic inflammation [4] Group 2: Mechanistic Insights - Gene Set Enrichment Analysis reveals that PAS-004's effects closely mirror ETS2 knockout profiles, showing a higher normalized enrichment score (-3.96 vs -3.56) and greater statistical significance (1.2 x 10⁻²⁵⁰ vs 3.7 x 10⁻⁷⁴) compared to selumetinib [4] - The ability of PAS-004 to block ETS2 signaling suggests it may target multiple cytokines, including TNFα, IL-23, and IL-1β, which are critical in chronic inflammatory diseases [4] Group 3: Future Potential - The company believes that PAS-004 has the potential to be a new oral treatment option for inflammatory diseases such as inflammatory bowel disease (IBD), based on low adverse events and tolerable safety data observed in Phase 1 clinical trials [4][5] - The preclinical results suggest that PAS-004's ability to block ETS2 signaling and target multiple cytokines opens the potential for testing in large market inflammatory indications [5]

Core Viewpoint - NANO Nuclear Energy Inc. has launched a significant irradiation testing program in collaboration with MIT to study the behavior of nitrate molten salts under radiation, which is crucial for the development of next-generation nuclear reactors [1][3][5] Group 1: Collaboration and Research Focus - The two-year collaboration with MIT will investigate the thermal and radiolytic behavior of nitrate molten salts for advanced nuclear energy systems [1][3] - The research is funded by NANO Nuclear with over $500,000 and will be supervised by Prof. Koroush Shirvan, a leading expert in nuclear systems engineering [2][3] - The study aims to fill the knowledge gap regarding the performance of molten salts under ionizing radiation, which is essential for nuclear environments [3][4] Group 2: Research Methodology and Expected Outcomes - MIT researchers will utilize advanced diagnostics to measure off-gassing behavior, thermal degradation, and long-term material stability of the salts [4][5] - The results will directly inform the design of microreactors that use molten salts for heat transfer and energy storage, enhancing safety and performance models [4][5] - The project is expected to conclude in 2027, with quarterly updates and final data delivery coordinated between MIT and NANO Nuclear [6] Group 3: Company Overview and Future Directions - NANO Nuclear is focused on becoming a diversified and vertically integrated company across five business lines, including microreactor technologies and nuclear fuel fabrication [7] - The company is developing several advanced reactor products, including the KRONOS MMR Energy System and the portable LOKI MMR [8][9] - NANO Nuclear's subsidiaries are also exploring commercial applications of micronuclear reactor technology in space and developing a domestic HALEU fuel fabrication pipeline [10][11][12]

AS Tallink Grupp (registration code 10238429, location and address at Sadama 5, 10111 Tallinn) held its Annual General Meeting of Shareholders on 20 May 2025 at 11 AM at the conference centre of Tallink SPA & Conference Hotel, at the address Sadama 11a, Tallinn. 66 shareholders were registered as attending at the Annual General Meeting of Shareholders, who owned 567,914,814 votes/shares (the amount of represented share capital 266,919,962.58 EUR), forming 76.38% of AS Tallink Grupp share capital. Resolutio ...

The annual general meeting of VOW ASA has today approved all of the proposed resolutions in the notice of the general meeting dated 29 April 2025. The minutes from the general meeting are enclosed as appendices to this notice. For more information, please contact: Cecilie Brænd Hekneby, CFO, Vow ASATel: +47 99 29 38 26Email: cecilie.hekneby@vowasa.com About Vow ASA Vow and its subsidiaries Scanship, C.H. Evensen and Etia are passionate about preventing pollution. The company's world leading solutions conv ...

Drilling Intersects Wide Zones of Higher-Grade Gold Mineralization at the Boin Gold Deposit VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Newcore Gold Ltd. ("Newcore" or the "Company") (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce additional drill results from the 35,000-metre drill program underway at the Company’s 100% owned Enchi Gold Project ("Enchi" or the "Project") in Ghana. Shallow Reverse Circulation ("RC") drilling at the Boin Gold Deposit ("Boin") intersected multiple wide zo ...

Steve McLean Named Interim Chief Financial OfficerLAS VEGAS, May 20, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced that Dennis Logan, the Chief Financial Officer of the Company, submitted his resignation effective May 31, 2025. Mr. Logan will be leaving the Company to pursue other opportunities. Mr. Logan has served as the Chief Financial Officer of the Company since 20 ...

ST. JOHN'S, Newfoundland and Labrador, May 20, 2025 (GLOBE NEWSWIRE) -- Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces that it has received new orders totaling more than $3 million for Kraken Synthetic Aperture Sonar (SAS). The Kraken SAS systems will be integrated on small and medium-class uncrewed underwater vehicles (UUVs) for clients in Asia Pacific, Europe, and North America. “We continue to see high demand for our synthetic aperture sonar on uncrewed systems, esp ...

Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company’s listing on such exchange is not affected by the receipt of the Notice SINGAPORE, May 20, 2025 (GLOBE NEWSWIRE) -- FBS Global Limited (NASDAQ: FBGL) disclosed that it had received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that FBGL is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s ordinary shares (the “Ordinary Shares”) on the Nasdaq ...